Dr Reddy's measures for success
India''s Dr Reddy''s Laboratories has launched roadshows for a debut ADR that will mark the first US listing attempt by an Asian pharmaceutical company.
Investor presentations for an 11.5 million unit issue began in Asia yesterday Thursday, with final pricing provisionally scheduled for April 11 after the completion of roadshows in Europe and the US next week. With Merrill Lynch as lead manager, the company is hoping to raise about $158 million based on today's close share price of Rp1,285 $27.59. Each ADR unit equals two shares and the overall offering will comprise about 18% of the company's share capital. With...
To continue reading, please login or register for free